Share on StockTwits
 

Vertex Pharmaceuticals (NASDAQ:VRTX) will be releasing its earnings data on Wednesday, January 29th. Persons interested in registering for the company’s earnings conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 79.37 on Tuesday. Vertex Pharmaceuticals has a one year low of $43.57 and a one year high of $89.96. The stock’s 50-day moving average is $74.21 and its 200-day moving average is $74.72. The company’s market cap is $18.553 billion.

Several analysts have recently commented on the stock. Analysts at UBS AG upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday, January 6th. They now have a $99.00 price target on the stock, up previously from $84.00. On the ratings front, analysts at Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, October 31st. Finally, analysts at Credit Suisse cut their price target on shares of Vertex Pharmaceuticals from $80.00 to $78.00 in a research note to investors on Wednesday, October 30th. They now have a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $93.29.

In other Vertex Pharmaceuticals news, Director Bruce Sachs sold 8,300 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $84.47, for a total transaction of $701,101.00. Following the transaction, the director now directly owns 38,210 shares of the company’s stock, valued at approximately $3,227,599. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.